title: Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer.
abstract: Renal cell carcinoma (RCC) is a heterogeneous disease as reflected in its presentation and clinical course, pathological subtypes, nuclear grades and molecular biology. Emerging data indicate that renal tumors express a variety of molecular tumor markers and unique patterns of gene expression. Clinically the disease behaves quite heterogeneously, with courses ranging from indolent to highly aggressive. Surgical monotherapy or as part of a multimodal approach remains the standard of care for most cases of RCC. Radical or partial nephrectomy is associated with a 5-year cancer specific survival (CSS) of 85-97% for pT1 tumors. Unfortunately, 20% of patients have either locally advanced or node positive (N+) RCC while another 22% have metastatic RCC (mRCC) at presentation. Unlike the outcomes in early localized disease, survival rates for N+ patients are poor and patients with mRCC are rarely cured despite aggressive multimodal therapy. Classic cytotoxic chemotherapy has repeatedly been shown to have little effect and only 5-20% of patients with mRCC respond to immunologic agents such as interferon and/or interleukin. Cytoreductive nephrectomy with systemic immunotherapy is associated with few cures with median survivals of 12-24 months. Recent advances in our understanding of the molecular origins and pathways of RCC have led to the development of more effective targeted therapies. Here we review the molecular pathways that define the pertinent therapeutic targets in RCC and the clinical data for these new and promising agents.
authors: Department of Medical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, 333 Cottman Avenue, Philadelphia, PA 19111, USA.
authors: Naomi B
authors: NB
authors: Haas
authors: Robert G
authors: RG
authors: Uzzo
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000098:blood supply / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D007680:Kidney Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000201:enzymology; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases
references: Nat Genet. 1997 May;16(1):68-73
references: 9140397
references: J Urol. 2006 Feb;175(2):459-62
references: 16406971
references: Lancet Oncol. 2005 Jul;6(7):491-500
references: 15992698
references: Blood. 2005 Feb 1;105(3):986-93
references: 15459012
references: Invest New Drugs. 2005 Aug;23(4):357-61
references: 16012795
references: Am J Pathol. 1999 Aug;155(2):517-26
references: 10433944
references: Clin Cancer Res. 2004 Apr 15;10(8):2584-6
references: 15102658
references: J Clin Oncol. 2006 Mar 20;24(9):1363-9
references: 16446323
references: Blood. 2003 May 1;101(9):3597-605
references: 12531805
references: Ann Surg Oncol. 2007 Feb;14(2):759-65
references: 17103075
references: Ann Intern Med. 2006 Nov 7;145(9):660-4
references: 17088579
references: Am J Pathol. 1994 Aug;145(2):356-64
references: 7519827
references: J Urol. 2005 Jun;173(6):1889-92
references: 15879769
references: Cancer. 2005 Dec 1;104(11):2323-33
references: 16240452
references: Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):1047-52
references: 11792863
references: Oncogene. 2000 Dec 27;19(56):6680-6
references: 11426655
references: J Clin Oncol. 2005 May 1;23(13):2900-2
references: 15860848
references: N Engl J Med. 2006 Dec 14;355(24):2542-50
references: 17167137
references: Annu Rev Genet. 1986;20:231-51
references: 2880556
references: N Engl J Med. 2005 Dec 8;353(23):2477-90
references: 16339096
references: Urol Clin North Am. 2003 Aug;30(3):423-36
references: 12953746
references: Ann Intern Med. 1984 Dec;101(6):798-9
references: 6497196
references: J Urol. 2006 Feb;175(2):425-31
references: 16406965
references: Mol Carcinog. 2001 Jul;31(3):161-70
references: 11479925
references: Mol Cancer Ther. 2006 Apr;5(4):995-1006
references: 16648571
references: Lancet. 2006 Oct 14;368(9544):1329-38
references: 17046465
references: J Biol Chem. 1993 Oct 25;268(30):22825-9
references: 8226793
references: Semin Oncol. 1995 Feb;22(1):3-8
references: 7855617
references: N Engl J Med. 2007 Jan 11;356(2):115-24
references: 17215529
references: Urol Clin North Am. 1993 May;20(2):303-21
references: 8493752
references: Lancet. 2001 Sep 22;358(9286):966-70
references: 11583750
references: N Engl J Med. 2003 Jul 31;349(5):427-34
references: 12890841
references: J Clin Oncol. 2005 Aug 10;23(23):5294-304
references: 15998902
references: CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
references: 15661684
references: J Surg Oncol. 2005 Sep 1;91(3):173-80
references: 16118771
references: Lancet. 2004 Feb 21;363(9409):594-9
references: 14987883
references: Clin Cancer Res. 2003 Jan;9(1):327-37
references: 12538485
references: Adv Cancer Res. 1998;72:141-96
references: 9338076
references: Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425
references: 15674877
references: JAMA. 2006 Jun 7;295(21):2516-24
references: 16757724
references: Curr Urol Rep. 2007 Jan;8(1):19-30
references: 17239313
references: Eur J Cancer. 2006 Aug;42(12):1875-80
references: 16806903
references: JAMA. 1995 Feb 15;273(7):564-70
references: 7837390
references: N Engl J Med. 2001 Dec 6;345(23):1655-9
references: 11759643
references: Hum Mol Genet. 1994 Dec;3(12):2169-73
references: 7881415
references: Cancer Res. 2006 Jun 1;66(11):5549-54
references: 16740688
references: N Engl J Med. 2007 May 31;356(22):2271-81
references: 17538086
references: Ann Intern Med. 2005 Aug 16;143(4):313-4
references: 16103482
references: Cancer. 2006 Nov 15;107(10):2375-83
references: 17048248
references: N Engl J Med. 2007 Jan 11;356(2):125-34
references: 17215530
references: J Clin Oncol. 2006 Oct 1;24(28):e48
references: 17008686
references: Cancer Res. 2004 Oct 1;64(19):7099-109
references: 15466206
references: J Urol. 2005 Jun;173(6):1903-7
references: 15879772
references: Arch Dermatol. 2006 Nov;142(11):1477-9
references: 17116839
references: Nature. 1994 Jun 30;369(6483):756-8
references: 8008069